Evaluation of Efficacy and Safety of Pazopanib Combined with TGI/CIV(nab⁃Paclitaxel+ Gemcitabine + Ifosfamide/cyclophosphamide +Irinotecan + Vinorelbine) in the Treatment for Children or Adolescents with Recurrent/refractory Rhabdomyosarcoma--an Open-label, Single-arm, Single-cente,phase II Clinical Trial

NCT06816771 Phase 2 RECRUITING

To evaluate the efficacy and safety of pazopanib combined with TGI/CIV chemotherapy in children and adolescents with recurrent or refractory rhabdomyosarcoma.

Details

Lead sponsor	Shandong Cancer Hospital and Institute
Phase	Phase 2
Status	RECRUITING
Enrolment	38
Start date	2025-02
Completion	2026-12-31

Conditions

• Rhabdomyosarcoma, Recurrent, Refractory

Interventions

• pazopanib
• TGI chemotherapy
• CIV chemotherapy

Primary outcomes

• Objective Response Rate(ORR) — Up to 4 cycles of chemotherapy (each cycle is 21 days)
  Defined as the proportion of patients who achieved complete response (CR) and partial response (PR) according to RECIST v1.1

Countries

China